Course Detail

Dyslipidemia is one of the major risk factors for coronary artery disease, stroke, and peripheral vascular disease. Strategies for primary and secondary prevention have been developed and published by panels of experts and are intended to serve as guidelines for management of patients at various levels of risk for cardiovascular disease. This course reviews the guidelines for diagnosis and pharmacologic management of dyslipidemia in general and at-risk populations. Complex case studies are the basis for applying the current guidelines to the pharmacologic management of patients.

Learning Objectives:

1. Describe the type of evidence upon which the 2013 ACC/AHA Blood Cholesterol guidelines were based;
2. List the 4 statin benefit groups based on ASCVD risk for secondary and primary prevention;
3. State the populations for whom moderate intensity and high intensity statin therapy are recommended;
4. List the routine monitoring parameters for therapeutic efficacy and toxicity for statin therapy;
5. Given a patient case, recommend an appropriate drug therapy regimen to reduce the risk of ASCVD events; and
6. List the patient populations from whom PSCK9 agents might be considered.

CE: 2.0 Contact Hours
Universal Activity Number (UAN): 0025-0000-15-171-H04-P
Expiration Date: 11/12/2018
Course Number: Ke-CN#CVD001V2
Instructor: David S. Roffman, PharmD, BCPS/Cardiology, Professor, University of Maryland School of Pharmacy

This course is sponsored in part by an educational grant from the Maryland Department of Health and Mental Hygiene and the Institute for a Healthiest Maryland.

Click here for additional course details.